US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Long-Term Incentive Plan - grant of share options to primary insiders

Tromsø, Norway, 18 December 2024 - The Board of Directors in ArcticZymes Technologies ASA (the "Company") has decided to grant 335,000 share options to senior management under the Company's long-term incentive plan.The strike price of the options are NOK 15.00 per share.The options will have 12 months waiting period, 36 months vesting period and 12 months exercise period. The options are granted in accordance with the Company's guidelines for remuneration to senior management approved by the Annual General Meeting on 20 May 2021. The following primary insiders have been granted options:

ArcticZymes Expands SAN HQ Portfolio with Two Advanced Solutions Tailored for Cell, Gene and Vaccine Biomanufacturers

Tromsø, Norway, December 9, 2024 – ArcticZymes Technologies (OSE:AZT) introduces two cutting-edge products, SAN HQ ELISA SensoPlus and SAN HQ GMP neo, designed specifically to meet the evolving demands of the cell, gene and vaccine biomanufacturing sector.The new SAN HQ ELISA SensoPlus represents a next-generation innovation for detecting trace amounts of SAN HQ nucleases during therapeutic manufacturing processes. With over a fivefold increase in sensitivity compared to its predecessor, this ELISA kit ensures precise monitoring while offering significant workflow benefits. Features such as

ArcticZymes' M-SAN HQ Sets New Standard for Measles Virus Purification with Unmatched DNA Clearance and High Recovery Rates

Tromsø, Norway – November 21, 2024 – ArcticZymes Technologies ASA (OSE: AZT), is proud to highlight the exceptional performance of our M-SAN HQ nuclease in the purification of recombinant measles viruses (MV), as detailed in a recent publication in the Journal of Chromatography A. The study demonstrates how integrating M-SAN HQ nuclease with heparin affinity chromatography streamlines MV purification, achieving unmatched levels of both purity and yield.Innovative Approach to MV Purification The study, titled "Highly Pure Measles Virus Generated by Combination of Salt-Active Nuclease

rcticZymes Technologies - Primary insider trading

(Tromsø 11 November 2024) Olav Lanes,  VP R&D and applications has on 11 November purchased 5.000 shares in ArcticZymes Technologies ASA for NOK 13,90 per share. Following this transaction holds Mr. Lanes 7.000 shares and 100.000 options in the company.Marit Sjo Lorentzen, VP Operations has on 11 November purchased 5.000 shares in ArcticZymes Technoloiges ASA for NOK 13.88 per share. Following this transaction holds Mrs. Lorentzen 25.331 shares and 100,000 options in the company. This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the

ArcticZymes Technologies - Primary insider trading

(Tromsø 08 November 2024) Frank Mathias, Chairman of the Board has on 07 November purchased 2.000 shares in ArcticZymes Technologies ASA for EUR 1.194 per share. Following this transaction holds Mr. Mathias 9.000 shares in the company.This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the Norwegian Securities Trading Act. For additional information, please contactBørge SørvollCFO+4795290187ir@arcticzymes.com About ArcticZymes Technologies ASA ArcticZymes Technologies is

ArcticZymes Technologies - Primary insider trading

(Tromsø 07 November 2024) Michael Akoh, CEO has on 07 November purchased 7.660 shares in ArcticZymes Technologies ASA for NOK 13.26 per share. Following this transaction holds Mr. Akoh 7.660 shares and 200.000 options in the company.Sharon Brownlow,  Board member has on 7 November purchased 10.570 shares in ArcticZymes Technoloiges ASA for GBP 0.9378 per share. Following this transaction holds Mrs. Brownlow 10.570 shares in the company. This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12

ArcticZymes Technologies - Primary insider trading

(Tromsø 06 November 2024) Frank Mathias, Chairman of the Board has on 06 November purchased 7.000 shares in ArcticZymes Technologies ASA for EUR 1.242 per share. Following this transaction holds Mr. Mathias 7.000 shares in the company.Børge Sørvoll, CFO has on 6 November purchased 5.000 shares in ArcticZymes Technoloiges ASA for NOK 14.00 per share. Following this transaction holds Mr. Sørvoll 100.428 shares and 280,000 options in the company. This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and

ArcticZymes Technologies announces commercial strategic Transformation and Q3 2024 Financial results

Tromsø, Norway, November 6th, 2024 – ArcticZymes Technologies (OSE: AZT) reported revenues of NOK 24.1 million and an EBITDA of NOK -2.3 million for the third quarter of 2024.Financial Highlights: · Revenue for Q3 2024 was NOK 24.1 million, compared to NOK 31.2 million in Q3 2023. Year-to-date revenue totals NOK 81.7 million (9M 2023: NOK 90.6 million). · Revenue for the quarter was in particular impacted by lower sales to two key accounts. · Biomanufacturing revenue has grown for the third consecutive quarter, demonstrating resilience in a challenging macroeconomic environment.

ArcticZymes Highlights Industry-Leading Success at ESGCT 2024

Rome, Italy – October 24, 2024 – ArcticZymes Technologies ASA (OSE: AZT), a global leader in enzyme innovation for bioprocessing, is excited to unveil breakthrough developments presented at the prestigious European Society of Gene and Cell Therapy (ESGCT) 2024 conference.The annual ESGCT conference is renowned for spotlighting breakthrough innovations in gene and cell therapy. It acts as a global stage for companies to showcase the latest scientific and technological achievements impacting their work in the biotherapeutics industry.   In this context, ArcticZymes salt active nucleases

ArcticZymes Technologies to present at the Pareto Securities 15th Healthcare Conference

(Tromsø, 19 September 2024) ArcticZymes Technologies ASA (OSE:AZT) will present at Pareto Securities 15th Healthcare Conference in Stockholm taking place today, 19 September 2024.Estimated start of the presentation will be at 13.10 CET. Speaker will be CEO, Michael Akoh Please find the presentation enclosed For further information:Børge SørvollCFO+47 950 90 187ir@arcticzymes.com

ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper published in Select Science on Advancing Viral Vector Manufacturing

September 17th, 2024, Tromsø, Norway — ArcticZymes Technologies (OSE: AZT) has released a timely whitepaper in Select Science titled "Efficient Chromatin Removal in Viral Vector Manufacturing Using Salt-Active Nucleases." As global attention on salt-active nucleases increases, this whitepaper reinforces ArcticZymes' leadership by offering crucial insights that help viral vector manufacturers optimize their downstream processing (DSP) and make informed decisions.The peer-reviewed studies cited in this paper will help leverage rising interest about Salt Active Nucleases and guide the

ArcticZymes Technologies ASA - Minutes form Annual General Meeting 2024

(Tromsø 26. June 2024) The Annual General Meeting of ArcticZymes Technologies ASA (OSE:AZT) was held today, 26. June 2024 as a virtual meeting with electronic participation.Attached to this announcement are the minutes of the Annual General Meeting in Norwegian and an English translation. All items on the agenda, except for point 9; board authorization to increase the share capital, were adopted. For further information, please contact:Børge SørvollCFO+47 952 90187borge.sorvoll@arcticzymes.com This information is subject to the disclosure requirements pursuant to section 5 -

ArcticZymes Technologies Announces Nomination of Dr. Frank Mathias as Chairman of the Board

Tromsø, Norway – June 25, 2024 – ArcticZymes Technologies (OSE:AZT) is pleased to announce the nomination of Dr. Frank Mathias as the new Chairman of the Board.Dr. Mathias is the CEO at Oxford Biomedica, a leading pure-play CDMO within the cell and gene therapy industry. Dr. Mathias was previously the CEO of Rentschler Biopharma SE, which he successfully developed into a leading global, full-service CDMO. Prior to Rentschler, Dr. Mathias served as CEO of Medigene AG, a publicly listed immuno-oncology company. During his 30-year career, Dr. Mathias has held senior roles at leading global

ArcticZymes Technologies executes contract with consortium for Advanced therapies enzyme project funded by The Research Council of Norway

Tromsø, Norway, June 17, 2024 - ArcticZymes Technologies ASA (OSE: AZT) has today executed a contract with The Research Council of Norway, securing up to 11.8 MNOK for a collaborative project aimed at supporting the advanced therapy biomanufacturing sector.This follows a previously announced research grant awarded by the Norwegian Research Council. The agreements with the Norwegian Research Council and the project partners, the University of Tromsø - The Arctic University of Norway, and SINTEF Industri have now been finalized, marking the project's commencement. The project has been named

ArcticZymes Technologies ASA - resignation of board member

Tromsø, Norway, 2nd April 2024 - Board member Edgar Koster has informed the board that he will resign from the board with immediate effect for personal reasons.The remaining board complies with the requirements regarding board composition and will still constitute a quorum. Dr Marie Roskrow,  Chairman of the Board,  commented, "on behalf of my colleagues and myself,  I would like thank Edgar very much for his contribution to the Company over the past year and we wish him well for the future." For more information, please contact:Chairman of the BoardDr. Marie Roskrow+44 (0)7496

ArcticZymes Technologies ASA Q4 and 12M 2023 results

Tromsø, Norway, February 1st, 2024 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 28.4 million and an EBITDA of NOK 2.0 million for the fourth quarter of 2023.Highlights from Q4 and 12 months 2023 · ArcticZymes Technologies (AZT) had Q4 sales of NOK 28.4 million (Q4 2022: NOK 28.2 million) and sales for the whole year 2023 of NOK 118.9 million (12M 2022: NOK 137.0 million, NOK 122.0 million adjusted for Covid effects in 2022) · AZT had a positive EBITDA for Q4 of NOK 2.0 million (Q4 2022: NOK 1.3 million) and a positive EBITDA for the whole year of NOK 22.2 million (

ArcticZymes Technologies ASA: Invitation to presentation of Q4 2023 results

The Company will host a Q4 2023 presentation for investors, analysts and media at 08:30 CET on Thursday, 1 February, 2024 at Høyres Hus, Stortingsgata 20, Oslo.The presentation will be given by CEO, Michael Akoh, CFO, Børge Sørvoll and VP Corporate Development, Jeremy Gillespie. The presentation can also be followed as a live webcast from Hegnar TV on https://channel.royalcast.com/landingpage/hegnarmedia/20240201_2/ or www.arcticzymes.com. It will be possible to post questions through the webcast console. The report for Q4 and 12 months 2023 will be available on www.newsweb.no and on

ArcticZymes Technologies launches T7 RNA Polymerase

Tromsø, Norway, December 21, 2023 – ArcticZymes Technologies ASA (OSE: AZT) launches T7 RNA PolymeraseArcticZymes Technologies (AZT) today announces the launch of its new product, T7 RNA Polymerase. Serving customers within the Molecular Tools segment, the T7 RNA Polymerase is intended for use in molecular research and diagnostics. The enzyme precedes the planned launch of a bioprocessing grade T7 RNA polymerase scheduled for 2024. The launch of the T7 RNA Polymerase is an example of ArcticZymes exploiting synergies between its business segments. While the field of RNA therapeutics is

ArcticZymes Technologies announces Partnership with Biomatter

Tromsø, Norway, December 19, 2023 – ArcticZymes Technologies ASA (OSE: AZT) enters into an agreement with Biomatter (Biomatter Designs UAB) to develop new enzyme-based products.ArcticZymes Technologies (AZT) has entered a partnership agreement with Biomatter, a leading enzyme design company. Leveraging Biomatter’s AI-driven Intelligent Architecture[TM] platform, the companies will co-develop new and improved products for AZT’s enzyme portfolio. The first focus project will be to explore the SAN portfolio in terms of new functions, properties and IP. The Intelligent Architecture[TM]

ArcticZymes Technologies ASA Q3 and 9M 2023 results

Tromsø, Norway, November 2[nd], 2023 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 31.2 million and an EBITDA of NOK 7.3 million for the third quarter of 2023Highlights from Q3 and 9 months 2023 · ArcticZymes Technologies (AZT) had Q3 sales of NOK 31.2 million (Q3 2022: NOK 29.3 million) and sales for the first 9 months of NOK 90.6 million (9M 2022: NOK 108.8 million, NOK 93.8 million adjusted for Covid effects in 2022) · AZT had a positive EBITDA for Q3 of NOK 7.3 million (Q3 2022: NOK 2.8 million) and a positive EBITDA for the first 9 months of NOK 20.2 million (9M

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe